Bastiano Sanna - 10 Feb 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Cell & Genetic Therapies
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
10 Feb 2023
Net transactions value
-$1,593,878
Form type
4
Filing time
14 Feb 2023, 16:08:54 UTC
Previous filing
03 Feb 2023
Next filing
16 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Tax liability $265,486 -902 -1.3% $294.33 66,368 10 Feb 2023 Direct
transaction VRTX Common Stock Tax liability $1,294,448 -4,340 -6.5% $298.26 62,028 13 Feb 2023 Direct
transaction VRTX Common Stock Sale $33,944 -113 -0.18% $300.39 61,915 13 Feb 2023 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1.
F2 Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $300.39 (range $300.00 to $300.79).